Rejuveron Transitions to Become a Clinical Stage Company as Rejuvenate Biomed Starts Ground-breaking Clinical Trial in Age-Related Muscle Wasting Disease, Sarcopenia

press release  ·  REJ-22-01

Schlieren, Zürich, Switzerland  ·  29 March 2022

Rejuveron Life Sciences AG (‘Rejuveron’), a Zürich-based biotechnology company developing therapies to promote healthy aging, today announced that Rejuvenate Biomed NV (‘Rejuvenate’) has commenced its first Phase 1 clinical trial assessing the company’s lead candidate RJx-01 for the treatment of sarcopenia. 

This is the first program in the Rejuveron pipeline to enter clinical trials and marks its maturation from a preclinical to clinical stage company. Rejuveron was a lead investor in Rejuvenate’s €15.7 million Series B funding in October 2021 and will ultimately acquire a majority shareholding. 

See the Rejuvenate full press release here.

Dr. Matthias Steger, PhD, MBA, CEO of Rejuveron said: 

“Over the past four years, the Rejuvenate team has demonstrated that its approach can be used to develop new patent-protected combination drugs based on known prescription medicines. This platform has resulted in a promising first drug candidate, with the wider application being to deliver therapeutics with a meaningful impact on the treatment and prevention of multiple age-related diseases by tackling their root causes. This strikes right at the heart of Rejuveron’s purpose: making therapies happen for people to stay healthier for longer.

About Rejuveron

Rejuveron is a clinical-stage biotechnology company creating therapies to improve healthy aging. Its experienced drug discovery and development team applies a deep understanding of the biology of aging, alongside technological advances in biopharmaceutical R&D, to progress a new generation of medicines that will help people to age better and live longer. 

Through its programs, each uniquely focused on preventing, repairing, or reversing the hallmarks of aging, Rejuveron is advancing a therapeutic pipeline that ranges from drug discovery to the clinic. Rejuveron’s business model is to create or acquire innovative programs, each being held within a wholly-owned or majority-owned company. 

Co-founded in 2019 by entrepreneurial scientist, Matthias Steger, and visionary investor, Christian Angermayer, Rejuveron has state-of-the-art incubator laboratory facilities and offices at its headquarters in Zürich’s Bio-Technopark (Switzerland),  New York (USA), as well as program teams located in Spain and Belgium.

Follow us on LinkedIn and Twitter


For media enquiries

At the company  ·  +41 79 500 9824
Charles Consultants  ·  +44 7968 726585